Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 12/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 11/20 | 0.40 |
| ▸ | TSHR | P16473 | 9/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 9/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 8/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.40 |
| ▸ | LMNA | P02545 | 6/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | PDE9A | O76083 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30462875 | 1.00 | CYP1A2 (0.40) | CYP1A2CYP3A4CYP2C19TSHRCYP2C9 | |
| SCHEMBL25257307 | 0.92 | CNR1 (0.40) | CYP1A2CYP3A4CYP2C19TSHRCYP2C9 | |
| SCHEMBL30462867 | 0.92 | CNR1 (0.40) | CYP1A2CYP3A4CYP2C19TSHRCYP2C9 | |
| SCHEMBL30462744 | 0.88 | GRM7 (0.43) | CYP1A2CYP3A4CYP2C19TSHRCYP2C9 | |
| SCHEMBL25258177 | 0.88 | GRM7 (0.43) | CYP1A2CYP3A4CYP2C19TSHRCYP2C9 | |
| SCHEMBL25262061 | 0.87 | CNR1 (0.39) | CYP1A2CYP3A4CYP2C19TSHRCYP2C9 | |
| SCHEMBL30462789 | 0.87 | CNR1 (0.39) | CYP1A2CYP3A4CYP2C19TSHRCYP2C9 | |
| SCHEMBL24252480 | 0.87 | CNR1 (0.40) | CYP1A2CYP3A4CYP2C19TSHRCYP2C9 | |
| SCHEMBL25261079 | 0.87 | CNR1 (0.38) | CYP1A2CYP3A4CYP2C19TSHRCYP2C9 | |
| SCHEMBL30462775 | 0.87 | CNR1 (0.38) | CYP1A2CYP3A4CYP2C19TSHRCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12522619-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2023-08-24 | — | — | US | disclosed |
| WO-2023137166-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2023137166-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265109-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | CYP1A2 2977/4885CYP3A4 2694/4885CYP2C19 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.